Daiichi Sankyo Company (TSE:4568) Could Be 34% Undervalued Following The Vanflyta China Deal
Investors are watching Daiichi Sankyo Company (TSE:4568) after its new agreement with Innovent Biologics to commercialize Vanflyta in China, providing fresh context for the stock’s recent performance and pipeline exposure.
See our latest analysis for Daiichi Sankyo Company.
The recent Vanflyta commercialization deal and new approvals for Datroway in the EU and U.S. come as Daiichi Sankyo Company's share price trades at ¥2,738. The stock has recorded a 6.37% 90 day share price return but a weaker 1 year total shareholder return of 23.62%. This suggests that short term momentum has improved, while longer term returns remain under pressure.
If this kind of pipeline news has your attention, it can be useful to widen your watchlist into other healthcare focused AI opportunities through the 6 healthcare AI stocks
Daiichi Sankyo Company now trades at a clear discount to both analyst targets and intrinsic value estimates. After the recent rebound, does that gap still point to upside, or does it say more about the risks being priced in?
Most Popular Narrative: 34% Undervalued
At a last close of ¥2,738 against a narrative fair value of ¥4,146, the gap on Daiichi Sankyo Company is clear and grounded in detailed forecasts.
Pipeline depth in antibody-drug conjugates (ADCs), supported by ongoing R&D investment and multiple upcoming pivotal data readouts and regulatory submissions (e.g., for breast, gastric, lung, and gynecological cancers), positions the company to capture higher-margin opportunities as precision medicine gains traction, which could further boost future net margins and earnings.
Want to see what underpins that valuation gap for Daiichi Sankyo Company? Revenue growth, margin shifts, and a richer earnings profile all sit at the core of this narrative. The timing and scale of those changes are mapped out in detail. The full story shows how those moving parts are expected to translate into the current fair value view.
Result: Fair Value of ¥4,146 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Daiichi Sankyo Company still faces concentration risk in key oncology drugs and potential pressure from tighter global drug pricing, which could challenge this upbeat narrative.
Find out about the key risks to this Daiichi Sankyo Company narrative.
Another View On Daiichi Sankyo Company’s Valuation
The narrative fair value of ¥4,146 suggests Daiichi Sankyo Company looks undervalued. However, the current P/E of 20.5x sits well above both the JP Pharmaceuticals industry at 14.9x and the peer average at 15.2x, even though it is below a fair ratio of 34.1x. That gap can point to either a quality premium or extra valuation risk. Which side do you think it falls on?
To see how this pricing gap lines up with the underlying numbers, take a closer look at the detailed valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mix of optimism and caution around Daiichi Sankyo Company, it helps to move quickly and review the underlying data yourself. To weigh up both sides of the story in one place, start with the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Daiichi Sankyo Company?
If you are serious about building a stronger portfolio, using the Simply Wall Street Screener to compare a range of opportunities can help sharpen your next decision.
- Spot potential value opportunities early by scanning screener containing 69 high quality undiscovered gems, which combine strong fundamentals with lower market attention.
- Strengthen your core holdings with companies from the solid balance sheet and fundamentals stocks screener (41 results) that focus on financial resilience and disciplined balance sheets.
- Lower overall portfolio stress by searching through 57 resilient stocks with low risk scores, which score well on stability and risk metrics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com